Drug Profile
ME 1036
Alternative Names: CP 5609; ME-1036Latest Information Update: 09 Feb 2009
Price :
$50
*
At a glance
- Originator Meiji Seika Kaisha
- Class Carbapenems
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Haemophilus infections; Methicillin-resistant Staphylococcus aureus infections; Pneumococcal infections; Skin and soft tissue infections
Most Recent Events
- 09 Feb 2009 Discontinued - Phase-I for Bacterial infections in North America (Parenteral)
- 09 Feb 2009 Discontinued - Preclinical for Haemophilus infections in Japan (Parenteral)
- 09 Feb 2009 Discontinued - Preclinical for Meticillin-resistant Staphylococcus aureus infections in Japan (Parenteral)